Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 16/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 16/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.62 |
| ▸ | TACR1 | P25103 | 2/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.62 |
| ▸ | HRH1 | P35367 | 2/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1875236 | 0.99 | CHRM3 (0.62) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL1875238 | 0.99 | CHRM3 (0.62) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL5540087 | 0.93 | CHRM3 (0.63) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL5540113 | 0.93 | CHRM3 (0.63) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL5536849 | 0.93 | CHRM3 (0.63) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL5533379 | 0.89 | CHRM3 (0.67) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL5532990 | 0.89 | CHRM3 (0.67) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL5544787 | 0.89 | CHRM3 (0.67) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL1875866 | 0.88 | CHRM3 (0.61) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL1875867 | 0.88 | CHRM3 (0.61) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100112061-A1 | Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis | GILEAD SCIENCES, INC. | 2010-05-06 | — | — | US | disclosed |
| EP-2114972-A2 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND BETA-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS | Gilead Sciences, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009060203-A1 | 3,4,6,7-TETRAHYDRO-1 H-PYRROLO[3,4-D]PYRIMIDINE-2,5-DIONES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2009-05-14 | — | — | WO | disclosed |
| WO-2008076269-A2 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND β-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS | GILEAD SCIENCES, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100112061-A1 | Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis | ADRB1, ADRB2, CHRM3 | CHRM3 3/4885CHRM2 5/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.